Impact of hepatitis B surface antigen positive grafts on liver transplantation in patients with benign and malignant liver disease

Abstract

AbstractHepatitis B surface antigen (HBsAg) persists after liver transplantation in almost all patients receiving HBsAg‐positive grafts. Chronic hepatitis B virus (HBV) infection is one of the main causes of hepatocellular carcinoma (HCC). We aimed to investigate possible interactions between HBsAg‐positive donors, HCC, HBV‐related transplant indication, and long‐term outcomes. This retrospective study enrolled 1176 patients from two centers between January 2015 and May 2019, of which 135 (11.5%) were HBsAg‐positive and 1041 (88.5%) were HBsAg‐negative donors. Cox regression models were fitted to study the association between variables and patient and graft survival. In univariate and multivariate analyses, the donor HBsAg status was not significantly associated with patient and graft survival in the entire cohort, but there was a significant interaction between HBsAg‐positive donors and HCC, independent of HBV‐related transplant indication. The cumulative incidence of patient and graft survival was significantly lower in the subgroup of HCC recipients receiving HBsAg‐positive grafts, but no significant difference was found in recipients with benign liver disease. In a subgroup analysis of HCC recipients, HBsAg‐positive donors were significantly associated with an increased risk of HCC recurrence (hazard ratio: 1.73; 95% confidence interval: 1.20–2.48; p = 0.003) and similar results were obtained after propensity score matching analysis. We showed excellent outcomes of using HBsAg‐positive grafts in patients with benign liver disease, regardless of HBV‐related transplant indications. However, positive grafts should be used with caution in recipients with HCC, which are associated with an increased risk of HCC recurrence.